{"id":57482,"date":"2023-05-26T22:03:10","date_gmt":"2023-05-26T20:03:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/"},"modified":"2023-05-26T22:03:10","modified_gmt":"2023-05-26T20:03:10","slug":"exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/","title":{"rendered":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives"},"content":{"rendered":"<div>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company\u2019s board of directors (the \u201cBoard\u201d).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/5\/Exicure_Logo_FINAL_Full_Color-072515.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg\"><\/a><\/p>\n<p>\nThe Company today announced that the Board fully supports the strategic vision of Mr. Kim and his ongoing efforts to maximize stockholder value. Mr. Kim will lead the Company\u2019s continuing efforts to identify and evaluate a range of potential strategic transaction alternatives, including transactions involving industries and businesses unrelated to our historical operations. These efforts include the possible sale of certain of the Company\u2019s assets, as well as exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. Mr. Kim will engage in discussions and oversee the due diligence process with parties potentially interested in transactions with the Company, and recommend to the Board whether any proposed transaction is in the best interests of the Company and its stockholders.<\/p>\n<p>\n\u201c<!-- no quote -->Exicure is committed to exploring strategic transaction alternatives, and the Board will facilitate this process,\u201d said Cheolho Jo of the Board. \u201c<!-- no quote -->The Board plans to proceed expeditiously, but will evaluate alternatives carefully for their ability to provide superior value to Exicure\u2019s stockholders.\u201d<\/p>\n<p>\nThere is no assurance that the review of strategic alternatives will result in any transaction or other strategic alternative.<\/p>\n<p>\n<b>About Exicure<\/b><\/p>\n<p>\nExicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exicuretx.com&amp;esheet=53408097&amp;newsitemid=20230526005198&amp;lan=en-US&amp;anchor=www.exicuretx.com&amp;index=1&amp;md5=5d8cbde6b2f12ef057a46c8cfdc081ec\" rel=\"nofollow noopener\" shape=\"rect\">www.exicuretx.com<\/a>.<\/p>\n<p>\n<b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company\u2019s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as \u201cplans,\u201d \u201cexpects,\u201d \u201cwill,\u201d \u201canticipates,\u201d \u201ccontinue,\u201d \u201cadvance,\u201d \u201cbelieves,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cintend,\u201d \u201ccould,\u201d and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management\u2019s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company\u2019s actual results to differ from those contained in the forward-looking statements, see the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 27, 2023, as updated by the Company\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMedia:<br \/>\n<br \/>Karen Sharma<br \/>\n<br \/>MacDougall<br \/>\n<br \/>781-235-3060<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x6b;&#x73;&#x68;&#x61;&#x72;&#x6d;&#x61;&#x40;&#x6d;&#x61;&#x63;&#x64;&#x6f;&#x75;&#x67;&#x61;&#x6c;&#x6c;&#x2e;&#x62;&#x69;&#x6f;\" rel=\"nofollow noopener\" shape=\"rect\">ksharma&#64;macdougall&#46;bio<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57482","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO&#8211;(BUSINESS WIRE)&#8211;Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-26T20:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives\",\"datePublished\":\"2023-05-26T20:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/\"},\"wordCount\":603,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230526005198\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/\",\"name\":\"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230526005198\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"datePublished\":\"2023-05-26T20:03:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230526005198\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230526005198\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/","og_locale":"en_US","og_type":"article","og_title":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend","og_description":"CHICAGO&#8211;(BUSINESS WIRE)&#8211;Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-26T20:03:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives","datePublished":"2023-05-26T20:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/"},"wordCount":603,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/","url":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/","name":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","datePublished":"2023-05-26T20:03:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230526005198\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57482"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57482\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}